Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA
Mandate

Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

August 13, 2020 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with its acquisition of a controlling interest of 62.7% of the French company Genkyotex SA, a leader in NOX inhibition therapies and listed on Euronext Paris and Euronext Brussels.

Calliditas is seeking to acquire all outstanding Genkyotex shares and will following completion of the control transaction, which is expected to close in October 2020, launch a mandatory cash tender offer on the same terms for the remaining shares.

Vinge’s team comprises Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Julia Hirschberg.





Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025